~~<i id='4A3CBF0CFA'><strike id='4A3CBF0CFA'><tt id='4A3CBF0CFA'><pre id='4A3CBF0CFA'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：leisure time 2025-08-17 14:38:25 Page View：575

Michel Pairet -- health business coverage from STAT — Michel Pairet Courtesy Boehringer Ingelheim

LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline.

There was obesity and liver disease, and computational biology and oncology. Then respiratory and inflammatory diseases. And don’t forget mental illness and retinal health. Oh, it was also the day the company launched another Humira biosimilar.

In other words, there was a whole lot for the company to discuss as it works to promote its breadth and build partnerships with academic researchers and other companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Language on climate change, ESG removed from company website of Montana GOP Senate candidate
Next article： Hepatitis C has a cure — but many Americans still lack access to it

focus

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

'The View' co

5:21BillGeddie.HeidiGutman/ABCBillGeddie,thetelevisionproducerwhoco-foundedABC's"TheView&q

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

What don’t we know about an Alzheimer’s drug side effect?

Illustration:AlexHogan/STAT;Photo:EisaiviaAPSincetheFDA’sapprovaloflecanemab(marketedasLeqembi)andMe